| Citation: |
HU Di, SHUI Yifang, MIAO Keke, LI Mengquan. Mendelian Randomized Study of Protective Effect of Statins on Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 165-171. DOI: 10.3971/j.issn.1000-8578.2025.24.0654
|
To genetically investigate the protective effects of statins on breast cancer.
Instrumental variables for the statin target gene HMGCR and five other cholesterol-regulated genes (LDLR, PCSK9, ABCG8, APOB, and NPC1L1) were obtained from previous expression quantitative trait locus (eQTL) studies. Cholesterol-regulated genes predicted by these instrumental variables served as the exposure factors. Mendelian randomization based on pooled data (SMR) was conducted to explore the genetic effects of exposure factors on the incidence risk of all breast cancers, ER+ breast cancer, and ER-breast cancer. Instrumental variables for total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) were derived from a previous human genome-wide association study and restricted to be chromosomally located within 100 kb of the above cholesterol regulatory genes; the instrumental variables could predict TC, LDL-C, or non-HDL-C levels under the regulation of the abovementioned cholesterol-associated genes which were used as exposure factors. Two-sample Mendelian randomization (IVW, MR-PRESSO, and MR-Egger) was used to explore the genetic effects of exposure factors on the risk of all breast cancers, ER+ breast cancer, and ER− breast cancer.
SMR analysis reported that elevated HMGCR expression was significantly associated with the increased incidence risk of all breast cancers and ER+ breast cancer (P=0.044 and P=0.039, respectively) but not with the change in incidence risk of ER− breast cancer (P=0.190); the other five regulatory genes were not significantly correlated with the change in incidence risk of all breast cancers, ER+ breast cancer, and ER− breast cancer (all P>0.05). IVW analysis reported that under the regulation of HMGCR, elevated levels of peripheral TC, LDL-C, and non-HDL-C significantly increased the incidence risk of all breast cancers (P=1.160e-05, P=1.248e-05, and P=1.869e-05) and the incidence risk of ER+ breast cancer (P=3.181e-04, P=2.231e-04, and P=3.520e-04), but they were not associated with a change in the incidence risk of ER− breast cancer (P=0.062, P=0.133, and P=0.055). The results of MR-PRESSO and MR-Egger analyses supported the IVW results.
Statins could reduce the incidence risk of ER+ breast cancer at the genetic level, but there is no such protective effects on ER− breast cancer.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834
|
| [2] |
胡志强, 游伟程, 潘凯枫, 等. 中、美两国癌症流行特征分析——《2023美国癌症统计报告》解读[J]. 科技导报, 2023, 41(18): 18-28. [Hu ZQ, You WC, Pan KF, et al. Epidemiological characteristics of cancers in China and America: Interpretation of the report of American cancer statistics, 2023[J]. Ke Ji Dao Bao, 2023, 41(18): 18-28.]
Hu ZQ, You WC, Pan KF, et al. Epidemiological characteristics of cancers in China and America: Interpretation of the report of American cancer statistics, 2023[J]. Ke Ji Dao Bao, 2023, 41(18): 18-28.
|
| [3] |
Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030[J]. Cancer Biol Med, 2021, 18(3): 900-909. doi: 10.20892/j.issn.2095-3941.2020.0523
|
| [4] |
Waks AG, Winer EP. Breast Cancer Treatment: A Review[J]. JAMA, 2019, 321(3): 288-300. doi: 10.1001/jama.2018.19323
|
| [5] |
Narii N, Zha L, Komatsu M, et al. Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases[J]. Breast Cancer Res Treat, 2023, 199(2): 315-322. doi: 10.1007/s10549-023-06917-z
|
| [6] |
Wang Y, Liu F, Sun L, et al. Association between human blood metabolome and the risk of breast cancer[J]. Breast Cancer Res, 2023, 25(1): 9. doi: 10.1186/s13058-023-01609-4
|
| [7] |
Ben Hassen C, Goupille C, Vigor C, et al. Is cholesterol a risk factor for breast cancer incidence and outcome?[J]. J Steroid Biochem Mol Biol, 2023, 232: 106346. doi: 10.1016/j.jsbmb.2023.106346
|
| [8] |
Ricco N, Kron SJ. Statins in Cancer Prevention and Therapy[J]. Cancers (Basel), 2023, 15(15): 3948. doi: 10.3390/cancers15153948
|
| [9] |
Zhao G, Ji Y, Ye Q, et al. Effect of statins use on risk and prognosis of breast cancer: a meta-analysis[J]. Anticancer Drugs, 2022, 33(1): e507-e518. doi: 10.1097/CAD.0000000000001151
|
| [10] |
Abdul-Rahman T, Bukhari SMA, Herrera EC, et al. Lipid Lowering Therapy: An Era Beyond Statins[J]. Curr Probl Cardiol, 2022, 47(12): 101342. doi: 10.1016/j.cpcardiol.2022.101342
|
| [11] |
Miziak P, Baran M, Błaszczak E, et al. Estrogen Receptor Signaling in Breast Cancer[J]. Cancers (Basel), 2023, 15(19): 4689. doi: 10.3390/cancers15194689
|
| [12] |
Võsa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression[J]. Nat Genet, 2021, 53(9): 1300-1310. doi: 10.1038/s41588-021-00913-z
|
| [13] |
GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues[J]. Science, 2020, 369(6509): 1318-1330.
|
| [14] |
Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association studies of lipids[J]. Nature, 2021, 600(7890): 675-679. doi: 10.1038/s41586-021-04064-3
|
| [15] |
Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci[J]. Nature, 2017, 551(7678): 92-94. doi: 10.1038/nature24284
|
| [16] |
Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets[J]. Nat Genet, 2016, 48(5): 481-487. doi: 10.1038/ng.3538
|
| [17] |
刘佳, 周星彤, 孙强. 多灶性/多中心性乳腺癌研究进展[J]. 协和医学杂志, 2024, 15(3): 632-641. [Liu J, Zhou XT, Sun Q. Research Progress of Multifocal/Multicentric Breast Cancer[J]. Xie He Yi Xue Za Zhi, 2024, 15(3): 632-641.] doi: 10.12290/xhyxzz.2023-0562
Liu J, Zhou XT, Sun Q. Research Progress of Multifocal/Multicentric Breast Cancer[J]. Xie He Yi Xue Za Zhi, 2024, 15(3): 632-641. doi: 10.12290/xhyxzz.2023-0562
|
| [18] |
何国珍, 刘晓, 员晓云, 等. 中医药防治乳腺癌相关信号通路的研究进展[J/OL]. 中华中医药学刊: 1-19 [2024-05-06]. http://kns.cnki.net/kcms/detail/21.1546.R.20240506.1130.002.html. [He GZ, Liu X, Yun XY, et al. Research progress of signaling pathways related to the prevention and treatment of breast cancer by traditional Chinese medicine[J/OL]. Zhonghua Zhong Yi Yao Xue Kan: 1-19 [2024-05-06]. http://kns.cnki.net/kcms/detail/21.1546.R.20240506.1130.002.html.]
He GZ, Liu X, Yun XY, et al. Research progress of signaling pathways related to the prevention and treatment of breast cancer by traditional Chinese medicine[J/OL]. Zhonghua Zhong Yi Yao Xue Kan: 1-19 [2024-05-06]. http://kns.cnki.net/kcms/detail/21.1546.R.20240506.1130.002.html.
|
| [19] |
Murto MO, Simolin N, Arponen O, et al. Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer[J]. JAMA Netw Open, 2023, 6(11): e2343861. doi: 10.1001/jamanetworkopen.2023.43861
|
| [20] |
Watson R, Tulk A, Erdrich J. The Link Between Statins and Breast Cancer in Mouse Models: A Systematic Review[J]. Cureus, 2022, 14(11): e31893.
|
| [21] |
O'Grady S, Crown J, Duffy MJ. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells[J]. Med Oncol, 2022, 39(10): 142. doi: 10.1007/s12032-022-01733-9
|
| [22] |
Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial[J]. Breast Cancer Res Treat, 2013, 138(2): 499-508. doi: 10.1007/s10549-013-2473-6
|
| [23] |
Goda AE, Elsisi AE, Sokkar SS, et al. Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination[J] Toxicol Appl Pharmacol, 2020, 404: 115185.
|
| [24] |
Kamal A, Boerner J, Assad H, et al. The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with In Situ or Early-Stage Invasive Breast Cancer[J]. Int J Mol Sci, 2024, 25(17): 9587. doi: 10.3390/ijms25179587
|
| 1. |
吴杨，隋雨桐，李斌鹏，韩路拓，姜家康. 激酶/转录因子信号通路调控肺癌机制及中医药干预的研究进展. 世界中医药. 2025(01): 142-147+154 .
| |
| 2. |
曹家瑞，冯博，马纯政，陈伟霞，喻江凡，曹莎莎，张振予，欧阳文慧. 中医药调控JAK/STAT信号通路干预肺癌的机制研究进展. 中国实验方剂学杂志. 2025(09): 265-276 .
| |
| 3. |
梁帅，尹怡，刘湘花，汪保英，骆文龙，龙云凯，任振杰，王祥麒. 升降理肺消瘤汤对Lewis肺癌小鼠免疫炎性反应和JAK2/STAT3信号通路的影响. 辽宁中医药大学学报. 2024(04): 27-32 .
| |
| 4. |
张彩蝶，靳艳，张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响. 天津医药. 2024(04): 362-366 .
| |
| 5. |
孙喜，王召路，贾谨睿，王梦洋，孙润卓，王鹏，史新娥. 虫草素及其在生猪养殖中的应用. 畜牧兽医杂志. 2024(04): 1-7 .
| |
| 6. |
兰春燕，杨小兰，贺雪峰，赵丹，杨海燕. 甘草苷对胃癌荷瘤小鼠免疫功能的调节作用及机制研究. 中国药房. 2024(15): 1862-1867 .
| |
| 7. |
张景淇，郭静，陈娅欣，蒲玥衡，向俊杰. 中药调控肺癌相关信号通路研究进展. 中国实验方剂学杂志. 2024(19): 233-244 .
| |
| 8. |
张孟恩，韩睿，徐超，庞训胜，王世琴. 地顶孢霉培养物在反刍动物生产中的应用研究进展. 中国畜牧杂志. 2024(12): 70-74 .
| |
| 9. |
高铭，丁美灵，雷紫琴，胡靖文，栾飞，曾南. 荆防败毒散及其中成药制剂研究进展. 中药药理与临床. 2023(05): 112-118 .
| |
| 10. |
朱亚兰，吕世文，曾晨欣，徐媛青. 苍术素对非小细胞肺癌细胞上皮间质转化的影响及机制研究. 浙江医学. 2023(10): 1013-1018 .
| |
| 11. |
陈才伟，陈家亮，李华娟，方芳，文方玲. 虫草素调节MAPK/AP-1信号通路对慢性阻塞性肺疾病大鼠肺组织损伤的影响. 临床肺科杂志. 2023(11): 1656-1661 .
| |
| 12. |
李翔子，王西双，范建伟，杨田野，王丽娟，孙颖，姚景春. 荆防合剂通过抑制JAK2-STAT3信号通路调节荨麻疹小鼠脾脏T淋巴细胞亚群的平衡. 中国中药杂志. 2022(20): 5473-5480 .
| |
| 13. |
沈栩岚，黄凌霞. 虫草素的抗癌机理. 蚕桑通报. 2022(02): 33-34 .
|
Figures(1) / Tables(6)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: